We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$121M
Cap. Flow
+$179M
Cap. Flow %
11.83%
Top 10 Hldgs %
46.72%
Holding
103
New
28
Increased
19
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$70.7M
2
UNH icon
UnitedHealth
UNH
+$33M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.5M
4
ELV icon
Elevance Health
ELV
+$28.2M
5
JBIO
Jade Biosciences
JBIO
+$27.1M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$22.4M
2
HOLX
Hologic
HOLX
+$18.7M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.7M
4
MRUS
Merus
MRUS
+$16.3M
5
INSM icon
Insmed
INSM
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
76
DELISTED
Merus
MRUS
$2.1M 0.14%
40,000
-345,821
-90% -$16.3M
SKIN icon
77
SkinHealth Systems
SKIN
$91.4M
$1.91M 0.13%
+1,000,000
New +$1.41M
MREO
78
Mereo BioPharma
MREO
$51.4M
$1.63M 0.11%
599,711
-87,242
-13% -$211K
YMAB
79
DELISTED
Y-mAbs Therapeutics
YMAB
$1.58M 0.1%
349,982
– –
TECX
80
Tectonic Therapeutic
TECX
$550M
$1.53M 0.1%
76,841
– –
MYO icon
81
Myomo
MYO
$41.7M
$1.52M 0.1%
704,275
– –
CALC icon
82
CalciMedica
CALC
$12.6M
$1.25M 0.08%
783,904
– –
EWTX icon
83
Edgewise Therapeutics
EWTX
$4.81B
$1M 0.07%
76,493
+4,193
+6% +$60.5K
KIDS icon
84
OrthoPediatrics
KIDS
$536M
$967K 0.06%
45,000
– –
ABVX
85
Abivax
ABVX
$10.9B
$956K 0.06%
125,000
– –
CBLL
86
CeriBell Inc
CBLL
$703M
$937K 0.06%
+50,000
New +$850K
SLNO
87
DELISTED
Soleno Therapeutics
SLNO
$838K 0.06%
10,000
-140,000
-93% -$10.5M
SEPN
88
Septerna Inc
SEPN
$1.76B
$798K 0.05%
75,456
-675,897
-90% -$5.57M
BCYC
89
Bicycle Therapeutics
BCYC
$275M
$695K 0.05%
+100,000
New +$797K
ADVM
90
DELISTED
Adverum Biotechnologies
ADVM
$618K 0.04%
287,246
– –
RVMD icon
91
Revolution Medicines
RVMD
$41.1B
$368K 0.02%
10,000
-74,784
-88% -$2.87M
DCTH icon
92
Delcath Systems
DCTH
$454M
$340K 0.02%
25,000
-207,722
-89% -$2.9M
IOBT
93
DELISTED
IO Biotech
IOBT
$268K 0.02%
192,670
– –
AXSM icon
94
Axsome Therapeutics
AXSM
$10.9B
$209K 0.01%
2,000
-15,000
-88% -$1.59M
ADPT icon
95
Adaptive Biotechnologies
ADPT
$3.9B
$117K 0.01%
10,000
– –
APGE icon
96
Apogee Therapeutics
APGE
$10.1B
– –
-16,000
Closed -$598K
HOLX
97
DELISTED
Hologic
HOLX
– –
-302,000
Closed -$18.7M
LIVN icon
98
LivaNova
LIVN
$4.69B
– –
-117,040
Closed -$4.6M
PTGX icon
99
Protagonist Therapeutics
PTGX
$8.73B
– –
-169,000
Closed -$8.17M
SNY icon
100
Sanofi
SNY
$102B
– –
-226,218
Closed -$12.5M
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Soleus Capital Management held 103 positions worth $1.51B, up 8.7% from $1.39B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Soleus Capital Management deployed $179M of net new capital in Q2 2025, opening 28 new positions and adding to 19 existing holdings. Its largest new stake was UnitedHealth: 86,250 shares worth $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was TG Therapeutics, an estimated $22.4M trimmed.

  • Soleus Capital Management's largest Q2 2025 buy was UnitedHealth: 86,250 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q2 2025, an estimated $70.7M increase.
  • Soleus Capital Management's biggest Q2 2025 reduction was TG Therapeutics, cutting an estimated $22.4M.
  • Soleus Capital Management fully exited Hologic in Q2 2025, selling an estimated $18.7M.
  • Soleus Capital Management's ten largest holdings make up 47% of its $1.51B portfolio in Q2 2025.
  • Soleus Capital Management opened 28 new positions and closed 8 in Q2 2025.
  • Soleus Capital Management's portfolio value rose 8.7% quarter-over-quarter to $1.51B.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.